NeoGenomics Launches New Website and Expands its Menu of Services
NeoGenomics, Inc. (NASD OTC BB:NGNM) NeoGenomics Inc., a laboratory Services and Research Company, announced the launch of its newly designed company web site. The web site reflects the company’s new organizational structure, which is focused into three clinical areas: Oncology, Prenatal, Molecular as well as its research and development activities.
The new web site www.neogenomics.org , also introduces the company’s new services in FISH (fluorescence In Situ Hybridization).
Fluorescence In Situ Hybridization (FISH)
Fluorescence In Situ Hybridization (FISH) can help identify subtle structural rearrangements, variant chromosomes, and translocations not readily discernable by classical cytogenetics. FISH relies on three technologies: cytogenetics, DNA hybridization and fluorescence microscopy to provide another level of chromosome analysis. FISH utilizes genetic probes comprised of specific nucleic acid sequences. These probes are then tagged with a fluorescent marker. FISH testing can be ordered in panels specific to a certain disease or disorder.
As a part of the company’s expansion of clinical testing services NeoGenomics has purchased the most advanced software and equipment from Applied Imaging. This will allow the NeoGenomics to provide the most sophisticated chromosome analysis for our clients and offer our clients faster turn around times.
Dr. Michael Dent, the company chairman and acting managing director stated, “These two initiatives will serve as important tools for our clients and their patients. The new web site is easy to navigate and provides information on all of our services and reflects our new focus on individual market segments.”
About NeoGenomics, Inc.
NeoGenomics, Inc. has established a state-of-the-art genetic testing laboratory in Ft. Myers, FL. The Company’s principle operations include providing cytogenetic and molecular diagnostic testing services to the physicians and hospitals.
The Company also conducts research activities to identify biomarkers for diseases such as preeclampsia and Ovarian cancer.
For additional information on NeoGenomics, please visit our web site at www.neogenomics.org .
Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company’s periodic filings with the SEC.
